Investigating how a protein switch affects the progression of estrogen receptor positive breast cancer
A SIM2s/SEMA7A Switch Drives ER+ Breast Cancer Progression
This study is looking at how a protein called Semaphorin 7a (SEMA7A) affects the growth and treatment resistance of estrogen receptor positive (ER+) breast cancer, with the goal of finding better treatment options for patients facing this challenging condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11044999 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Semaphorin 7a (SEMA7A) in the progression of estrogen receptor positive (ER+) breast cancer, which is a common and often deadly form of breast cancer. The study aims to identify how high levels of SEMA7A are linked to poor survival outcomes and resistance to standard therapies like Tamoxifen. By examining the mechanisms through which SEMA7A influences cancer cell survival and metastasis, the researchers hope to uncover new therapeutic targets that could improve treatment options for patients with advanced ER+ breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with estrogen receptor positive breast cancer, particularly those experiencing metastasis or resistance to current therapies.
Not a fit: Patients with non-estrogen receptor positive breast cancer or those who are not experiencing treatment resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve survival rates for patients with advanced ER+ breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in breast cancer, indicating potential for success in this novel approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Lyons, Traci — University of Colorado Denver
- Study coordinator: Lyons, Traci
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.